Artelo Biosciences Unveils Key Data on ART26.12 at British Pain Society's 57th Annual Meeting

June 04, 2024 -- Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, is set to present new preclinical data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society. The event, taking place from June 4-6, 2024, in Nottingham, UK, will feature presentations by Professor Saoirse O’Sullivan on the promising results of ART26.12 in managing pain associated with cancer and diabetes.

The presentations, “ART26.12, a Novel Fatty Acid-binding Protein 5 Inhibitor, shows Efficacy in Breast Cancer-Induced Bone Pain” and “The Effects of the Fatty Acid Binding Protein 5 Inhibitor ART26.12 in a Rat Model of Diabetic Neuropathy,” will discuss the efficacy of Artelo’s Fatty Acid Binding Protein 5 (FABP5) inhibitor for treating painful peripheral neuropathies and various cancers. Effective doses and plasma exposures align with previously published data on ART26.12 in treating oxaliplatin-induced peripheral neuropathy.

Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, emphasized the significance of these findings, stating, “We are pleased to be presenting these preclinical studies which underscore the broad therapeutic potential of ART26.12. Importantly, the data shows that oral treatment with ART26.12 was effective at reducing pain induced by cancer as well as diabetes, demonstrating that inhibiting FABP5 is a promising non-opioid, non-steroidal treatment strategy for pain.”

Professor O’Sullivan further noted, “We have now demonstrated that ART26.12 has an attractive safety profile and is effective in multiple preclinical models of peripheral neuropathy of diverse etiology. With the global burden of pain affecting millions, particularly those with cancer-induced bone pain and diabetic neuropathy, ART26.12 offers an innovative approach intended to address a critical need for safer, more effective analgesics.”

ART26.12 signifies a major step forward in Artelo’s mission to develop innovative therapies targeting lipid signaling pathways. The company plans to submit an Investigational New Drug application to the U.S. Food and Drug Administration for neuropathic pain treatment within the month.

About ART26.12:

Fatty Acid Binding Proteins (FABPs) are intracellular proteins that chaperone lipids, including endocannabinoids and fatty acids. FABP5, a member of this family, is overexpressed and linked to abnormal lipid signaling in various pathologies. ART26.12, Artelo’s lead FABP5 inhibitor, is a potent and selective inhibitor developed as a non-opioid, non-steroidal analgesic, with initial clinical trials planned for chemotherapy-induced peripheral neuropathy (CIPN). Artelo’s library of small molecule inhibitors of FABPs shows therapeutic promise for certain cancers, neuropathic and nociceptive pain, and anxiety disorders.

About Artelo Biosciences:

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to developing and commercializing proprietary therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system. The company is advancing a diverse portfolio of product candidates designed to address significant unmet needs in multiple diseases and conditions, such as anorexia, cancer, anxiety, pain, and inflammation. With a team of experienced biopharmaceutical executives and collaborations with esteemed researchers and technology experts, Artelo combines leading-edge scientific, regulatory, and commercial expertise to develop impactful therapies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!